Abstract

Lobectomy and systematic nodal dissection are still the standard for small-size (<3 cm) nonsmall cell lung cancer. There is growing interest in more parenchyma-sparing surgery, so-called sublobar resections (wedge resection or segmentectomy). Indeed, nonrandomised trials suggest that a segmentectomy may result in local control rates that are similar to lobectomy. Nonsurgical approaches, such as stereotactic ablative radiotherapy, consistently result in local control rates of ∼ 90% and survival rates that are comparable to lobectomy. Therefore, we are moving towards an era in which several therapeutic possibilities are available, that are probably equivalent from an oncological point of view. Further trials are needed to define the optimal therapy for individual patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.